Effects of pioglitazone on MKP-1 and TSP-1 expression in early stages of diabetic retinopathy induced by streptozotocin.
- Author:
Jian-yong WANG
1
;
Jian-guo SHEN
;
Jing-xia KONG
Author Information
- Publication Type:Journal Article
- MeSH: Animals; Diabetes Mellitus, Experimental; drug therapy; metabolism; Diabetic Retinopathy; drug therapy; metabolism; Hypoglycemic Agents; therapeutic use; Mitogen-Activated Protein Kinase 1; biosynthesis; genetics; Random Allocation; Rats; Rats, Sprague-Dawley; Thiazolidinediones; therapeutic use; Thrombospondin 1; biosynthesis; genetics
- From: Journal of Zhejiang University. Medical sciences 2006;35(5):529-534
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo explore the effects of pioglitazone on MKP-1 and TSP-1 expression in the early stages of diabetic retinopathy induced by streptozotocin (STZ) and the relevant mechanism in it.
METHODSDiabetic rats were induced by an intraperitoneal injection of STZ in SD rats. Thirty male SD rats were randomly divided into 3 groups: diabetes adding pioglitazone group (intragastric administration pioglitazone 20 mg x kg(-1) x d(-1)), diabetes adding BBS group and normal control group. The body weight and blood glucose were measured every two weeks. Eight weeks later, all rats were killed and the expression of TSP-1 and MKP-1 mRNA was quantified in retinal tissue by immunohistochemistry and reverse transcription-polymerase chain reaction (RT-PCR) respectively.
RESULTTSP-1 and MKP-1 concentrations were significantly increased in the diabetic rats' retinal tissue compared to the control rats. Diabetes groups adding pioglitazone caused the upregulation of TSP-1 and MKP-1 expression in the retina among the three groups.
CONCLUSIONPioglitazone treatment can significantly attenuate the evolutionary in the early stages of experimental diabetic retinopathy. Further studies should address the possible involvement of TSP-1 and MKP-1 in the correlational pathophysiology between pioglitazone and diabetic retinopathy.
